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Blood products are scarce resources requiring prudent
and reasoned allocation. The utilization of red blood
cells and platelets in terminally ill patients can be com-
plicated and requires guidelines tempered by individual-
ized considerations. Representative cases are
discussed in which blood products are requested or uti-
lized by patients at the end of life. Relevant literature is
reviewed and ethical issues pertaining to each case are
discussed. A practical approach to blood product utiliza-
tion at the end of life is suggested.
A
large number of resources are used to treat
patients at the end of life in our health care
system. Health care reform has focused atten-
tion on this critical issue. Transfusion medicine
is one area in which costly and scarce resources are uti-
lized routinely in patients who are either at the end of life
or who have little hope for recovery. Few studies have
addressed blood products specifically as an area ame-
nable to rationing.
Ethical principles can help guide decision-making in
allocating blood products for patients who are terminally
ill. In certain situations, ethical considerations may con-
flict. Beauchamp and Childress1 created the principlist
paradigm often used in medical ethics. The principle of
autonomy refers to the idea that the patient must consent
to or refuse medical treatment. Beneficence means that
the physician should act in the patient’s best interest.
Nonmaleficence is defined as not doing anything that is
likely to be harmful. Finally, justice is the idea that medical
care should be allocated fairly. The principles of benefi-
cence and autonomy are used to justify pursuing a course
of treatment that is best for the individual patient;
however, this can conflict with the principle of social
justice which promotes the idea that resources should be
fairly distributed.
Hurst and Danis2 attempt to provide a framework for
understanding and implementing bedside rationing. They
argue that clinical rationing does occur in certain situa-
tions. This type of rationing can occur in acute shortages,
when using limited but not “immediately strained”
resources, or when considering the benefit of adding
interventions in any given patient. They offer six require-
ments for fair bedside rationing. They argue that it should
be a closed system, meaning that everyone is subject to
the same constraints and limitations. They believe that
physicians should consider justice when formulating poli-
cies. In addition, the application of rationing should be
consistent but also allow some amount of flexibility for
individual exceptions. Finally, it should be transparent
and iterative, meaning that the policies are available to
everyone and reviewed and/or revised as needed.
Cases highlighting different types of blood bank
resource utilization issues at the end of life will be pre-
sented with a discussion of the ethical issues involved. The
first three cases are based on actual cases encountered in
our blood bank practice. The final case is hypothetical.
The cases have been modified to remove any identifying
patient information.
CASE 1
Sally is a 10-year-old girl with acute myeloid leukemia. She
underwent bone marrow transplantation but now her leu-
kemia has recurred. She has required crossmatched plate-
lets (PLTs) for the past two hospitalizations. Three days
ago her family made the difficult decision to treat Sally
with comfort measures only. Earlier today, she developed
epistaxis and the pathology resident is now contacted by
the pediatric team to approve a cross-matched PLT trans-
fusion. The pathology resident questions why the patient
should receive crossmatched PLTs at this stage in her
illness. The pediatric resident is incredulous and asks the
pathology resident how she can deprive a terminally ill
child of PLTs at this difficult and emotional time.
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Discussion of Case 1
More than 2 million apheresis-equivalent units of PLTs are
collected in the United States every year.3 As the process is
reasonably laborious, even a standard dose of PLTs is a
scarce resource. Cross-matched and HLA-matched PLTs
are exceedingly precious because of the difficulty involved
in their acquisition and the need to ensure an adequate
supply for patients who need them. Prevention of
improper PLT utilization requires careful oversight. Inap-
propriate transfusion is also an issue because blood prod-
ucts are not harmless and can cause sequelae including
infection, transfusion reactions, transfusion-related acute
lung injury, and the development of alloantibodies.
In evaluating this case, it is helpful to examine the
literature on the withdrawal of life support to better
understand current practice patterns. Studies have shown
that up to 10% of advanced cancer patients will suffer
some type of hemorrhage.4 In France, a study showed that
cancer patients receive 76% of the PLT transfusions.5 Asch
and colleagues6 studied the manner in which care is with-
drawn from patients at the end of life. Of the types of life
support studied, blood products were the first interven-
tion to be withdrawn. In an earlier study, the same authors
showed that physicians decide on withdrawal of life-
sustaining treatment based on concerns over scarcity,
cost, and invasiveness, although individual preferences do
exist.7 Based on these studies, the withdrawal of blood
products is a common practice near the end of life.
Using a social justice argument, it can be asserted that
cross-matched PLTs are not appropriate in a patient
whose status is palliative care only. Another patient should
not be deprived of cross-matched PLTs to provide them to
this terminally ill patient. In addition, the plateletpheresis
donor incurs health-related risk in providing PLTs. While
most adverse events are minor, some more serious
risks include thrombophlebitis, infection, and neurologic
injury.8 Severe reactions occur in approximately 3.22 in
10,000 donors per year.9 While a small percentage of
donors have a severe reaction, the number is high enough
to place limits on blood products to reduce these risks.
Furthermore, the financial cost of providing cross-
matched or HLA-matched PLTs is high. If health care
reform is going to be successful in controlling costs,
expensive interventions at the end of life will have to be
carefully examined and justified.
In this case, attempts could be made to control the
bleeding with packing and local hemostatic measures. If
the bleeding is prolonged and causes distress, PLTs (a
standard pooled dose) may be indicated.4 While cross-
matched PLTs are more likely to remain in circulation
longer and result in a prolonged increase in PLTs, a stan-
dard dose could help alleviate acute bleeding. The case
presented is a situation in which a trainee may not have
considered the scarcity of the resource in question and the
interventions that should reasonably be performed in a
patient who has been designated as comfort or palliative
care only. Alternatively, it could be argued by some who
oppose rationing in any form, that it would be unfair to
place limits on this resource or any other at the end of life.
However, if these specialized interventions are limited in a
clear policy, we believe that this would be justified. If such
a policy is adopted, educational programs designed for
trainees and clinicians could help in avoiding confusion in
this type of situation. In this case, the cross-matched PLTs
were not provided. It is unknown how long the patient
survived after this request.
CASE 2
Ms. S is a 42-year-old woman with metastatic ovarian car-
cinoma. She has undergone extensive radiation and che-
motherapy over the past 3 years. She is hospitalized with
new-onset gastrointestinal bleeding as the tumor has
eroded through the wall of the colon. The patient has been
evaluated and the bleeding is not amenable to emboliza-
tion or radiation. The only treatment that will sustain life is
blood transfusion. Current estimates indicate that the
patient will require 5 to 6 units of red blood cells (RBCs)
daily. The patient is hopeful that future treatment will be
curative and wants to have daily transfusions with the goal
that the bleeding will stop and additional treatment will
be possible. The physicians caring for the patient believe
that she is at the end of her life and the transfusions will
only serve to postpone the moment of death.
Discussion of Case 2
Approximately 17.3 million units of RBCs are collected
each year.3 While more abundant than PLTs, RBCs are
nonetheless a limited resource. Shortages are frequent
and blood drives are often required to maintain a continu-
ous supply, particularly for less common blood types.
Maintaining a continuous supply of 5 to 6 units per day is
likely to be a significant burden on the blood bank, espe-
cially if the patient has an unusual blood type and the
course of disease is prolonged. Interestingly, nature may
provide its own “rationing” in the case of blood transfu-
sions, in that patients who have been repeatedly trans-
fused with blood may develop alloantibodies that can
make obtaining compatible blood more difficult. Eventu-
ally, one could argue, the number of antigen-negative (or
compatible) units required may be impossible to obtain if
alloantibodies did develop.
Ethically, this is a difficult case as the patient has not
elected to discontinue aggressive care. The principle of
autonomy dictates care in many situations. Patients are
allowed to elect or decline medical care based on personal
preferences. Rationing has negative connotations and is
not generally condoned in our current health care system.
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However, limits can be placed, especially when a treat-
ment may have questionable medical benefit. In this case,
the physicians can argue that the transfusions are medi-
cally futile. Futility is variably defined but includes end-
of-life situations in which the treatment is very unlikely to
achieve the desired effect or lead to medical improve-
ment.10 Futility is a difficult ethical concept to invoke as it
is somewhat dependent on the goals of care. The patient
could argue that even one extra day of time with her family
is a reasonable goal. Balancing the patient’s preferences
against the needs of society is challenging in these
situations.
In resolving this case, a consultation from the hospi-
tal’s ethics committee was requested. Different options
were discussed by the committee. One idea was to suggest
that the patient’s family donate blood to the community
blood supply to offset her use; however, in this case the
sheer number of units required made this an untenable
option. It may also have been possible for the family to
organize a blood drive for the patient. Ultimately, the deci-
sion was made to discuss the scarcity of blood products
and limit the transfusions to a certain number per week
(one to two in this case). The patient and family agreed to
this plan. The patient was discharged to hospice care and,
interestingly, was alive on follow-up a couple of weeks
later, suggesting that the bleeding had subsided on its
own.
CASE 3
Ms. H is a 28-year-old woman who was in a motor vehicle
accident. She was transferred to a tertiary care center from
a community hospital with massive bleeding. The patient
used 100 units of RBCs and during this time it was neces-
sary to switch from D– to D+ blood. Due to dwindling
group O inventories, the intensive care unit was contacted
to alert the clinical team that the patient would need to
be transitioned to group A blood products. The team
acknowledged that the patient was not going to survive
but wished to keep the patient alive until the family
members could arrive to say goodbye.
Discussion of Case 3
This case illustrates the difficulties that can arise in
massive transfusion. In general, a first-come, first-served
approach is typically used if the transfusion is clinically
indicated. One issue involves the protection of scarce O–
units to accommodate other potential trauma patients. In
terms of transitioning to D+ blood, alloimmunization is
estimated to occur in approximately 20% to 25% of D–
patients who receive D+ RBCs.11-13 Many blood banks have
policies on switching patients to D+ blood in these types
of situations. This can be a difficult decision in a woman of
child-bearing age if she is expected to survive, although
that is not the case here.
The larger problem here is the depletion of the group
O inventory. The mortality rate of an acute hemolytic
transfusion reaction due to ABO incompatibility is
approximately 10%. In a massive transfusion situation
where isoagglutinins have been effectively washed out by
transfusion of out-of-group plasma, the risk of a fatal reac-
tion is probably much lower, although there are no clear
data. Depletion of the group O inventory is likely to cause
delay in transfusion of other patients, which could be
especially dangerous if there is another severe trauma
case. This particular situation is problematic because the
team is requesting massive blood product utilization after
they have determined that the patient will die. In this case,
the care is futile and the patient is using resources that
could be saved for another patient. Interestingly, at this
time, another trauma patient was also using large
numbers of group O units and additional RBCs had to be
acquired from a local community hospital.
In this case, it must be determined whether such a
request should be honored to attain this specific goal of
care. Accommodations are often made to allow family to
arrive, as in the case of terminally ill patients in the inten-
sive care unit. This situation is also expensive and could
potentially deprive another patient of a needed bed. This
case is somewhat similar in that a scarce resource is being
used solely to delay the moment of death with the possi-
bility that another patient will not receive a life-saving
treatment. The principle of social justice can be used to
justify a different course of action in this case, although it
is difficult to know where to draw the line. The transfu-
sions were not successful in keeping the patient alive long
enough for the family to arrive, in spite of the clinical
team’s best efforts.
CASE 4
Ms. R is a 35-year-old woman with metastatic breast
cancer who has elected to forego additional chemo-
therapy, recently entering hospice care. As she has meta-
static masses in her liver, her life expectancy is estimated
to be several months. On a routine visit with her oncolo-
gist, she complains of severe fatigue. Her hemoglobin level
is 7 g/dL. The oncologist feels that a RBC transfusion
would substantially improve the quality of the patient’s
remaining life. She discusses this with the patient who
agrees to have a transfusion.
Discussion of Case 4
In this case, a transfusion is very likely to significantly
improve the patient’s quality of life by improving her
fatigue. For this reason, it is ethically justified to provide
the blood. At the end of life, patients and families are often
concerned that if they elect hospice or comfort care they
will be abandoned by their physicians and their needs will
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be ignored.14 This concern is often centered on pain
management, but can also include other physical and
emotional support. A blood transfusion in these circum-
stances will help in meeting the goals of care at this point
in the course of illness.
SUGGESTED GUIDELINES
Transfusion at the end of life can be useful in certain situ-
ations, but may be justifiably limited in others. A parallel
can be drawn to the guidelines that have been suggested
for utilization of scarce resources during a pandemic.
Some argue that the most aggressive interventions should
be reserved for those patients who are more likely to leave
the hospital,15-17 while others believe that using this crite-
rion alone is problematic.18 Similarly, limiting the scarce
resources utilized for patients who are designated
“comfort/palliative care only” can be justified, in part, as
they will not recover. As suggested by Hurst and Danis, it is
important to have consistent guidelines that place limits
on product use, but can be modified to fit unusual
individual circumstances.2 The following are possible
examples based on the cases presented:
1. Exceedingly scarce resources such as crossmatched
and HLA-matched PLTs, granulocytes, and rare units
of blood should not be used in patients who have
transitioned to palliative or comfort care. Routine
blood products should be used sparingly and
requests should be approved by the transfusion medi-
cine service.
2. Transfusions in medically futile situations should be
avoided, if possible, and limited to the minimum
number of RBC transfusions necessary to ameliorate
symptoms of anemia. PLTs should also be limited to
the minimum necessary to control bleeding (if it is
causing significant patient distress, such as upper
airway bleeding). In the event that the frequency of
transfusions impacts resources available for other
patients (i.e., more than twice a week), the request
should be reviewed by the transfusion medicine
service. In determining whether care is futile at the
University of Michigan, a policy is in place that
requires the agreement of two independent physi-
cians. The hospital ethics committee is often con-
sulted in difficult cases.
3. If shortages of blood products arise, attempts should
be made to defer transfusion in patients at the end of
life to preserve the products for other patients. In
cases of shortages of D– blood, terminally ill patients
can be transiently transitioned to D+ blood if the
transfusion is necessary at all. Unusual requests such
as massive transfusion in a futile situation should not
be allowed. If agreement cannot be reached on this,
an ethics consult should be urgently requested.
4. Transfusion in stable, terminally ill patients requires a
careful analysis of the goals of care. Transfusions
should not be discouraged in patients for whom an
occasional transfusion is likely to alleviate primary
symptoms such as extreme fatigue. Large numbers of
transfusions, however, should be reviewed by the
transfusion medicine service.
Physicians working in transfusion medicine may find
it helpful to have institutional guidelines, such as these, in
place to ensure fair and proper utilization of blood prod-
ucts at the end of life. With a standard policy in place,
these decisions are less likely to seem arbitrary to the
treatment teams and patients. Educational sessions could
be employed to disseminate the guidelines and answer
questions in anticipation of the difficult situations that
may arise. These sessions could include discussions with
intensive care unit teams in the form of “ethics rounds” or
could be presented in didactic form at an established
ethics grand rounds presentation. Of course, no policy can
address all possible contingencies. Some issues will need
to be addressed on a case-by-case basis, particularly
when a shortage exists. In contentious or ambiguous
cases, consultation with a hospital ethics committee can
be extremely helpful. Empirical research is needed to fully
understand the attitudes of blood bank directors, physi-
cians, patients, and the general public regarding rationing
blood products.
In conclusion, utilization of blood products at the
end of life is a controversial issue. Careful analysis of
salient medical and ethical issues fosters the responsible
use of these resources. Formulating guidelines and pro-
moting communication between transfusion medicine
physicians and treatment teams ensures the optimal care
of each patient. With reasoned consideration of these
issues and their solutions, the ethical principles of
beneficence and social justice need not conflict.
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